EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Growth inhibition of common neonatal pathogens differs between bovine lactoferrin products

Kyra P Watral, David A Kaufman, Timothy J Boly, Jennifer R Bermick

Journal of Medical Microbiology · 2025

DOI: 10.1099/jmm.0.002056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Microbiology, 2025. Verfasst von Kyra P Watral und 3 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Graduate Program in Immunology, University of Iowa, Iowa City, IA, USA. Hauptthemen laut MEDLINE: Lactoferrin, Escherichia coli, Klebsiella pneumoniae, Anti-Bacterial Agents. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Infection is a leading cause of mortality during the first year of life, with the neonatal period being particularly high risk. It is critical to identify non-antibiotic approaches to improve neonatal infection outcomes due to the non-specific clinical signs of neonatal infection and negative consequences of early-life antibiotic exposure. Lactoferrin is a protein found in all mammalian milk that has a variety of antimicrobial properties. Clinical trials have shown that lactoferrin supplementation during the neonatal period decreases rates of sepsis. Knowledge Gap. It remains unclear if there is an optimal lactoferrin preparation for human neonates.

Aim

Compare bacterial growth inhibition capabilities between different commercially available bovine-derived lactoferrin (bLF) preparations. Methodology. This study uses a broth microdilution in vitro assay to directly compare the antibacterial effects and shelf stability of different bLF preparations against three common neonatal pathogens: Escherichia coli , Klebsiella pneumoniae and Streptococcus pneumoniae .

Results

Bacterial growth inhibition differed significantly between bLF manufacturers and between different bLF lots/batches from the same manufacturer. Approximately half of the bLF products demonstrated decreased bacterial growth inhibition capabilities within 7–14 days after solubilization.

Conclusion

These findings may help select optimal bLF products for clinical use in the neonatal population, but additional in vivo studies are needed to confirm our in vitro findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LactoferrinEscherichia coliKlebsiella pneumoniaeAnti-Bacterial AgentsStreptococcus pneumoniaeAnimalsCattleInfant, NewbornHumansMicrobial Sensitivity Tests

Stichwörter der Autor:innen

antibacterialbacterialactoferrinneonate

Substanzen

LactoferrinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Interdisciplinary Graduate Program in Immunology, University of Iowa, Iowa City, IA, USA.
  • Iowa Inflammation Program, University of Iowa, Iowa City, IA, USA.
  • Department of Pediatrics, Division of Neonatology, University of Virginia School of Medicine and Children's Hospital, Charlottesville, VA, USA.
  • Department of Pediatrics, Division of Neonatology, University of Iowa, Iowa City, IA, USA.

Förderung

  • NIAID NIH HHS
  • NIH

Zitieren

APA

Watral, K. P., Kaufman, D. A., Boly, T. J., & Bermick, J. R. (2025). Growth inhibition of common neonatal pathogens differs between bovine lactoferrin products. Journal of Medical Microbiology. https://doi.org/10.1099/jmm.0.002056

Vancouver

Watral KP, Kaufman DA, Boly TJ, Bermick JR. Growth inhibition of common neonatal pathogens differs between bovine lactoferrin products. Journal of Medical Microbiology. 2025. doi:10.1099/jmm.0.002056

BibTeX
@article{Watral2025,
  author = {Watral, Kyra P and Kaufman, David A and Boly, Timothy J and Bermick, Jennifer R},
  title = {Growth inhibition of common neonatal pathogens differs between bovine lactoferrin products},
  journal = {Journal of Medical Microbiology},
  year = {2025},
  doi = {10.1099/jmm.0.002056}
}
Kostenlos starten →